Showing 683 results
-
Media Release /
-
Media Release /In advanced progressive, nonfunctional NET, Afinitor is the first approved treatment for patients with lung NET and the first oral therapy for GI NETApproval helps fulfill unmet need as progressive,…
-
Media Release /
-
Media Release /- Cosentyx is the first and only interleukin-17A (IL-17A) antagonist approved for adult patients with active ankylosing spondylitis (AS) and psoriatic arthritis (PsA)- Approvals for both indications…
-
Media Release /
-
Media Release /- Cosentyx (secukinumab) is the first IL-17A antagonist to complete Phase III studies which demonstrated efficacy and assessed safety in ankylosing spondylitis (AS)(1)- Cosentyx provided improvements…
-
Media Release /
-
Media Release /- 55 of 59 patients experienced complete remissions in a single-arm study of the largest investigational CART therapy in children and young adults [1]- Additional data presented include analyses on…
-
Media Release /
-
Media Release /- Overall response rate at 3 months was 47% (7/15) in diffuse large B-cell lymphoma and 73% (8/11) in follicular lymphoma- Successful technology transfer enabling commercial scale-up of CTL019 cell…
